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1. Introduction 
1.1 Coronary artery disease  
Coronary artery disease (CAD) and its cardiovascular sequelae still represent the leading 
cause of mortality worldwide. The underlying disease, atherosclerosis, is characterized 
by a continuous damage of the vascular endothelium leading to endothelial activation 
and apoptosis, the development of endothelial dysfunction and subsequent 
atherosclerotic lesion formation. The initial step in the development of atherosclerosis is 
the damage of healthy endothelium and the exposure of vascular cells to various 
pathogenic factors.  Decreasing of antithrombotic and anticoagulatory properties of 
normal endothelium contribute to the formation of atherosclerotic plaque. Additionally, 
endothelial dysfunction is associated with a couple of inflammatory factors which 
increase plaque vulnerability. Therefore, the dysfunctional endothelium plays key role in 
plaque destabilization and erosion in the development and progression of CAD(Lerman 
and Zeiher, 2005).  
 
1.2 Circulating MV in CAD 
As a consequence of endothelial activation and dysfunction, CAD patients show 
increased plasma level of circulating microvesicle (MV)(Boulanger, et al., 2012), which 
represent small membrane vesicles with a size of 100 to 1000 nanometers (nm). MV, 
also referred to as microparticle, can be released from most cell types (circulating cells, 
vascular cells, and cardiomyoctyes)(Camussi, et al., 2010). Both cell activation and cell 
apoptosis can lead to MV liberation from cells. MV retain surface molecules from parent 
cells, as well as part of their cytosolic content during their formation and 
shedding(Boulanger, et al., 2006). However, MV are not merely inert debris that reflects 
cellular activation or injury. In contrast, they are important carriers of bioactive molecules 
(proteins, mRNAs and microRNAs (miRs)) playing essential roles in cell–cell cross talk. 
By transferring their biological content into recipient cells, MV are regarded as crucial 
regulators of cardiovascular health and disease, including activation of platelets and 
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endothelial cells (ECs), as well as regulation of inflammation and coagulation(Ray, et al., 
2008, Brill, et al., 2005, Owens and Mackman, 2011, Jansen, et al., 2013). Moreover, in 
human plasma, circulating MV have ideal characteristics as risk makers because they 
are stable and easily detectable by reliable quantitative techniques (annexin V capture 
assay and flow cytometry)(György, et al., 2011).  
There is increasing evidence indicating that MV are emerging as key players in 
cardiovascular disease development and progression. In patients with stable CAD, 
coronary calcification or ACS, both of platelet-derived microvesicle (PMV) and EMV 
(endothelial cell-derived microvesicle) are elevated(Jayachandran, et al., 2008, Mallat, et 
al., 2000, Simak, et al., 2006). In asymoptomatic patients with subclinical atherosclerosis, 
in contrast, levels of MV originating from leukocytes are increased(Chironi, et al., 2006). 
Similar findings were observed in patients with heart failure and valvular disease. In 
these pathologies, EMV, PMV and LMV (leukocyte-derived microvesicle) levels also are 
increased. Notably, plasma MV levels are also associated with clinical outcomes in 
several cardiometabolic diseases, including coronary artery disease, chronic renal failure, 
diabetes mellitus, and obesity(Heiss, et al., 2008, Amabile, et al., 2005, Werner, et al., 
2006, Koga, et al., 2005, Esposito, et al., 2006). Moreover, MV levels are modulated in 
other vascular diseases, including preeclampsia(González-Quintero, et al., 2003), 
inflammatory vasculitis(Brogan, et al., 2004), and antiphospholipid 
syndrome(Dignat-George, et al., 2004). 
Atherosclerotic plaques contain large numbers of MV, mostly from lymphocyte and 
monocyte-macrophage cells, and their levels increase in patients with high 
atherothrombosis risk(Rautou, et al., 2011). Therefore, significant increases in plasma 
LMV levels are associated with unstable plaques. In addition, numerous studies have 
revealed that PMV may contribute to platelet activation during atherothrombosis(Del 
Conde, et al., 2005, Siljander, 2011, Shantsila, et al., 2010). A recent study found that 
PMV enhanced normal platelet activation, and PMV may be effective targets for 
preventing platelet activation in CAD(Wang, et al., 2012). Furthermore, abundant 
evidences demonstrated that plasma EMV level is a novel biomarker of endothelial 
dysfunction. Indeed, Schiro et al. showed that carotid artery disease is associated with 
significantly elevated plasma levels of EMV(Schiro, et al., 2014). Similarly, 
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Bernal-Mizrachi et al. reported that high levels of EMV were associated with high risk 
lesions with multiple thrombi in cardiovascular disease (Bernal-Mizrachi, et al., 2004). All 
together, these findings indicate that plasma levels of MV could be of prognostic value for 
the occurrence of cardiovascular diseases. 
 
1.3 Circulating miRs in CAD 
The first miR was discovered by Lee and colleagues in 1993, isolating Lin-4 from the 
nematode Caenorhabditis elegans(Lee, et al., 1993). Since then, more than 1,700 miRs 
have been identified (www.mirbase.org). miRs are a class of short, non-coding RNAs of 
22 nucleotides length, and miRs negatively regulate gene expression 
posttranscriptionally through inhibiting translation from and/or inducing degradation of 
messenger RNAs(Lee and Ambros, 2001). Consequently, miRs have been associated 
with cardiovascular disease risk factors, such as myocardial infarction, atherosclerosis, 
CAD, heart failure, atrial fibrillation, hypertrophy and fibrosis(Fichtlscherer, et al., 2010, 
Small, et al., 2010, Corsten, et al., 2010, Gomes da Silva and Silbiger, 2014). Particularly, 
since miRs are significant regulators in inflammation, angiogenesis and apoptosis which 
are important characteristics of plaque vulnerability, they may play as key factors in 
atherosclerotic plaque formation and plaque rupture. Extracellularly circulating miRs are 
either associated with different types of vesicles (exosomes, MV, apoptotic bodies ) or 
bound to proteins (high-density lipoprotein, argonaute-2 (Ago2)) apparently without being 
encapsulated into vesicles(Arroyo, et al., 2011, Turchinovich, et al., 2011). Notably, 
vesicle-associated miRs appeared to be more stable than those not associated with 
vesicles(Köberle, et al., 2013). In particular, previous studies indicated that cells can 
selectively package miRs into MV and secreted miRs can act as signaling molecules 
mediating cell-cell communication altering function and phenotype of the target 
cells(Jansen, et al., 2013, Zhang, et al., 2010). In addition, increasing evidence shows 
that circulating miRs are altered in diverse cardiovascular pathologies (Jansen, et al., 
2016). Therefore, circulating miRs have emerged as a novel class of biomarkers for CAD 
patients(Loyer, et al., 2014). Importantly, high expressions of vasculoprotective miRs 
within MV show atheroprotective effects in experimental murine models of vascular injury 
and atherosclerosis(Jansen, et al., 2013, Zernecke, et al., 2009, Hergenreider, et al., 
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2012) and are associated with a reduced rate of major adverse cardiovascular events in 
patients with stable CAD(Jansen, et al., 2014).  
Whereas numerous studies explored the role of MV-bound miRs in patients with stable 
CAD, the influence of different stages of CAD (angiographically excluded CAD, stable 
CAD and ACS) on MV-miR expression is unclear. 
As miR-containing MV regulate vascular function and disease progression, a detailed 
exploration of miRs expression in circulating MV in patients with stable CAD, acute 
coronary syndrome (ACS) and angiographically excluded CAD would be of high interest 
to better understand the pathogenesis of CAD and develop novel therapeutic strategies. 
 
1.4 Aims 
In this study, we aimed to explore the expression and role of circulating MV-miRs in 
patients with angiographically excluded CAD, stable CAD and ACS. 
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2. Material and Methods 
2.1 Study subjects 
Between August 2012 and July 2013, 233 patients presenting in our outpatient and 
emergency department were enrolled in the study. Informed consent was obtained from 
all patients and the ethics committee of the University of Bonn approved the study 
protocol (approval number 05/12). According to the results of clinical presentation, 
laboratory parameters and coronary angiography, patients were classified into 3 groups: 
angiographic exclusion of obstructive coronary artery disease (<50% stenosis of a major 
coronary artery, named as no CAD (NCAD), n=41), stable CAD (n=77) and acute 
coronary syndrome (ACS, n=62, Figure 1).  
 
2.2 Preparation of blood samples 
Venous blood was drawn under sterile conditions from the cubital vein and was buffered 
using sodium citrate (for MV quantification) or ethylenediaminetetraacetic acid (EDTA, for 
miR analysis). Additional blood samples for routine analyses were obtained. Blood was 
centrifuged at 1500g for 15 minutes followed by centrifugation at 13,000g for 2 minutes to 
generate platelet-deficient plasma. The deprived plasma samples were immediately 
stored in −80 °C. Annexin V/CD 31 positive MV levels were measured freshly with flow 
cytometry by using Annexin V-FITC and CD31-PE (BD Pharmingen). Platelet-deficient 
plasma was stored in −80 °C until miR levels were analyzed. 
 
2.3 MV collection and RNA isolation 
RNA was isolated from circulating MV by using TRIzol-based miR isolation protocol. 
250 μl total plasma was centrifuged at 20,000g for 30 minutes at 4 °C to pellet circulating 
MV as previously described(Jansen, et al., 2013, Jansen, et al., 2014), (Jansen, et al., 
2017). The pellet was diluted in 250 μl RNase-free water and then diluted in 750 μl 
TRIzol® LS in order to measure MV-miRs levels. Caenorhabditis elegans miR-39 
(cel-miR-39, 5nM, Qiagen) was spiked in TRIzol for normalization of miR content as 
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described(Fichtlscherer, et al., 2010). To increase the yield of small RNAs, the RNA was 
precipitated in ethanol at −20 °C overnight with glycogen (Invitrogen). 
 
2.4 Sorting of MV subspecies 
For sorting of MV subspecies, 250 µl platelet-free plasma was stained with CD31-PE, 
and CD42b-APC (BD Pharmingen) and the corresponding isotype and negative controls. 
Stained plasma was incubated for 45 minutes in dark at room temperature according to 
the manufactures suggestions. To sort MV subspecies, a FACSAria™ III Flow Cytometer 
(BD Biosciences) was used. Vesicles between 100–1000 nm in diameter were gated for 
sorting. CD31+/CD42b−, CD31+/CD42b+ and CD31−/CD42b− MV were gated, sorted 
and collected as previously described(Jansen, et al., 2016, Jansen, et al., 2014). 
RNase-free water was added to the sorted MV to reach a total volume of 250 μl, which 
was diluted in 750 μl TRIzol® LS in order to measure MV-miRs levels. Cel-miR-39 was 
spiked in TRIzol for normalization of miR content as described(Jansen, et al., 2014). To 
increase the yield of small RNAs, the RNA was precipitated in ethanol at −20 °C 
overnight with glycogen (Invitrogen). 
 
2.5 Quantification of miRs by quantitative PCR 
RNA was quantified using Nanodrop spectrophotometer (Nanodrop Technologies Inc). 
10 ng of the total RNA was reversely transcribed using TaqMan® miR reverse 
transcription kit (Applied Biosystems) according to the manufactures protocol. miR-126, 
miR-222, miR-let7, miR-21, miR-30, miR-92, miR-139, miR-199 and miR-26 in circulating 
MV were detected by using TaqMan® miR assays (Applied Biosystems) on a 7500 HT 
Real-Time PCR machine (Applied Biosystems). For all miRs, a Ct value above 40 was 
defined as undetectable. Values were normalized to cel-miR-39 and are expressed as 
2−[CT(miR)−CT(cel-miR−39)] log10. For all PCR experiments, samples were run in triplicates. 
 
2.6 Cell culture and endothelial MV generation 
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Human coronary artery endothelial cells (HCAEC, PromoCell) were cultured in 
endothelial cells (ECs) growth media with endothelial growth media Supplement Mix 
(Promocell) under standard cell culture conditions (37 °C, 5 % CO2). Cells of passage 
4–7 were used when 70–80 % confluent. EMV were generated from HCAEC as 
previously described(Jansen, et al., 2013). Briefly, confluent cells were starved by 
subjecting to basal media without growth media supplements for 24 hours to induce 
apoptosis. After starvation, supernatant of apoptotic HCAEC was collected and 
centrifuged at 1500g for 15 minutes to remove cell debris. The supernatant was 
centrifuged (20,000g, 40 minutes) to pellet EMV. The obtained EMV were washed in 
sterile phosphate buffered saline (PBS, pH 7.4) and pelleted again at 20,000g for 
40 minutes. Pelleted EMV were resuspended in sterile PBS and used freshly. For all 
experiments, EMV were used at a concentration of 2000/µl, which has been shown an 
effective concentration to explore functional effects of EMV in previous 
experiments(Jansen, et al., 2013, Rautou, et al., 2011, Jansen, et al., 2012). 
 
2.7 miRs sorting in oxLDL EMV by quantitative PCR 
In order to generate EMV from ECs under oxidized low-density lipoprotein (oxLDL) 
conditions, confluent HCAEC were stimulated with 50μg/ml oxLDL for 24 hours and then 
subjected to basal media without growth media supplements for 24 hours to generate 
EMV. EMV derived from oxLDL-treated HCAEC were defined as oxLDL EMV. Pelleted 
oxLDL EMV were resuspended in sterile PBS and used freshly. Total RNA was isolated 
out of oxLDL EMV by TRIzol® (Invitrogen) extraction method according to instruction of 
the manufacturer. To increase the yield of small RNAs, the RNA is precipitated in ethanol 
at −20 °C overnight with glycogen (Invitrogen). RNA was quantified using Nanodrop 
spectrophotometer (Nanodrop Technologies Inc). 10 ng of the total RNA was reversely 
transcribed using TaqMan® miR reverse transcription kit (Applied Biosystems) according 
to the manufactures protocol. miR-126, miR-222, miR-let7, miR-21, miR-30, miR-92, 
miR-139, miR-199 and miR-26 in oxLDL EMV were detected by using TaqMan® miR 
assays (Applied Biosystems) on a 7500 HT Real-Time PCR machine (Applied 
Biosystems). The data are presented as the fold change in miR expression normalized to 
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RNU6B (fold change = 2−ΔΔCT). For all miRs, a Ct value above 40 was defined as 
undetectable. For all PCR experiments, samples were run in triplicates. 
 
2.8 miR-92 expression in oxLDL EMV and oxLDL-treated HCAEC  
In order to generate oxLDL EMV from HCAEC under different oxLDL concentrations, 
confluent HCAEC were stimulated with PBS, 10μg/ml, 20μg/ml, 50μg/ml and 100μg/ml 
oxLDL for 24 hours and then subjected to basal media without growth media 
supplements for 24 hours to generate different oxLDL EMV. Pelleted oxLDL EMV were 
resuspended in sterile PBS and used freshly. Total RNA was isolated out of oxLDL EMV 
and oxLDL-treated HCAEC by TRIzol® (Invitrogen) extraction method according to 
instruction of the manufacturer. To increase the yield of small RNAs, the RNA is 
precipitated in ethanol at −20 °C overnight with glycogen (Invitrogen). RNA is quantified 
using Nanodrop spectrophotometer. Then, 10 ng of the total RNA was reversely 
transcribed using TaqMan® miR reverse transcription kit (Applied Biosystems) according 
to the manufacturers protocol. Taqman® miR assays (Applied Biosystems) were used to 
measure miR-92 levels on a 7500 HT Real-Time PCR machine (Applied Biosystems). 
The data are presented as fold change in miR expression normalized to RNU6B (fold 
change = 2−ΔΔCT).  
 
2.9 STAT3 inhibition in vitro  
HCAEC were pre-incubated with PBS (as control), 2µM/L, 4µM/L and 6µM/L Stattic 
(Calbiochem), a non-peptitic specific STAT3 inhibitor, for 4 hours and then subjected to 
basal media without growth media supplements for 24 hours to generate different EMV. 
Total RNA was isolated out of EMV and Stattic-treated HCAEC by TRIzol® (Invitrogen) 
extraction method according to instruction of the manufacturer. To increase the yield of 
small RNAs, the RNA is precipitated in ethanol at −20 °C overnight with glycogen 
(Invitrogen). RNA is quantified using Nanodrop spectrophotometer. Then, 10 ng of the 
total RNA was reversely transcribed using TaqMan® miR reverse transcription kit 
(Applied Biosystems) according to the manufacturers protocol. Taqman® miR assays 
(Applied Biosystems) were used to measure miR-92 levels on a 7500 HT Real-Time PCR 
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machine (Applied Biosystems). The data are presented as fold change in miR expression 
normalized to RNU6B (fold change = 2−ΔΔCT).  
 
2.10 Boyden chamber assay  
HCAEC (1*105) were seeded onto the upper compartment of Boyden chambers (BD 
falcon) with transwell polycarbonate inserts (8.0µm pore size) for 24 hours. EMV, 
EMVmiR-92-downregulated, EMVmock-transfected or vehicle was added into the lower well of the 
Boyden chamber, incubating for 6 hours to allow for cell migration. The insert was 
removed, and the upper side of the insert, was scraped off with a rubber cell lifter. The 
inserts were fixed with 4% paraformaldehyde and stained with DAPI. Cell migration was 
quantified by counting cells of 3 random microscopic fields (×100) in each well. 
 
2.11 Scratch Assay  
HCAEC were grown to confluence and scratched with a sterile pipette (10ul). After the 
scratch, growth factor-deprived medium was added to the cells and cells were stimulated 
with 2000 AnnV+ EMV/µl, 2000 AnnV+ EMVmiR-92-downregulated /µl, 2000 AnnV+ 
EMVmock-transfected /µl, or vehicle. Then, cells were photographed on a marked position at 0, 
3 or 4 and 6 hours. The remaining cell free area was measured and correlated (in 
percent) to the initial scratched area. 
 
2.12 HCAEC proliferation assay by fluorescence microscopy 
HCAEC in basal medium were deprived of growth media supplements and coincubated 
with EMV, EMVmiR-92-downregulated, EMVmock-transfected or vehicle for 24 hours. Next, the cells 
were pulsed with BrdU (10µM, BD) for 6 hours. Cells were fixed and denatured. BrdU 
incorporation was detected using rat anti-BrdU (Abcam) and secondary antibody 
anti-rat-cy3 (Jackson ImmunoResearch). Nuclei were stained with DAPI (Vector 
labaratories). Zeiss Axiovert 200M microscope and AxioVision software were used to 
take photographs. 
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2.13 HCAEC proliferation assay by flow cytometry 
HCAEC in basal medium were deprived of growth media supplements for 24 hours, 
followed by stimulation with EMV, EMVmiR-92-downregulated, EMVmock-transfected or vehicle in 
growth media with supplements for 24 hours. Cell cycle analysis was performed using 
Bromodeoxyuridine (BrdU) Flow Kit (BD) according to the instructions of the 
manufacturer. In brief, cells were pulsed with BrdU (10 µM) for 3 hours. Cells were 
trypsinated, fixed and permeabilized. BrdU incorporation was detected using 
FITC-conjugated anti-BrdU antibody for 20 minutes at room temperature followed by 
incubation with 7-aminoactinomycin (7-AAD) viability staining solution in staining buffer 
overnight at 4 °C. Stained cells were analyzed using FACSCalibur (BD). 
 
2.14 HCAEC tube formation assay 
HCAEC tube formation was assessed with an assay based on the use of a growth factor 
reduced (GFR) Matrigel. After thawing overnight at 4°C, 250 µL GFR Matrigel was placed 
into each well of cold 24-well plates using cold pipette tips, and the GFR Matrigel was 
allowed to incubation for 30 minutes in room temperature. HCAEC were placed in the 
wells coated with GFR Matrigel at 4*104 cells per well in deprived of growth media 
supplements and coincubated with EMV, EMVmiR-92-downregulated, EMVmock-transfected or 
vehicle for 24 hours under standard cell culture conditions (37 °C, 5 % CO2). Wells 
containing PBS were used as controls. Four randomly selected fields of view were 
analyzed, and tube formation was quantified by measuring the number of junctions and 
the number of nodes. Digital images of microtiter wells sections were obtained using 
Zeiss Axiovert 200M microscope. Data were analyzed with the Image-Pro Plus software. 
 
2.15 Taqman miR array 
RNA (more than 500ng) was converted to cDNA by priming with a mixture of looped 
primers (Human Mega Plex Primer Pools, Applied Biosystems). MiR profiles in isolated 
MV from stable CAD (n=5) and ACS (n=5) patients were assessed using TaqMan® Array 
miR Cards (Applied Biosystems) for a total of 384 unique assays specific to human miRs 
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under standard real-time PCR conditions. PCR was carried out on an Applied 
Biosystems 7900HT thermocycler using the manufacturer’s recommended program. 
Detailed analysis of the results was performed using the Data Analysis v3.0 Software 
(Applied Biosystems). CT values above 35 were defined as undetectable. 
 
2.16 RT2 Profiler PCR Array Gene Expression  
HCAEC were pre-incubated with EMV, EMVmiR-92-downregulated, EMVmock-transfected or vehicle 
for 24 hours. Total RNA was isolated out of HCAEC by TRIzol (QIAGEN) extraction 
method according to instruction of the manufacturer. RNA is quantified using Nanodrop 
spectrophotometer. Then, more than 500ng of the total RNA was reversely transcribed 
using RT2 First Strand Kit (QIAGEN) according to the manufacturers protocol. RT² 
Profiler PCR array analysis was performed to measure the expression of 84 key genes 
involved in modulating the biological processes of angiogenesis. PCR was carried out on 
an Applied Biosystems 7500 HT real-time PCR machine. Detailed data analysis report 
was performed using the Data Analysis v3.0 Software (Applied Biosystems) and 
exported from the QIAGEN web portal at GeneGlobe. CT values above 35 were defined 
as undetectable. 
 
2.17 Transfection of HCAEC  
To generate EMVmiR-92-downregulated and EMVmock-transfected, HCAEC were transfected with 
miR-92 inhibitor (1nM, all from Applied Biosystems) using lipofectamine 2000 (Invitrogen) 
for 24 hours and exposed to media without growth media supplements for 24 hours to 
generate modified EMV. For siRNA experiments, HCAEC were transfected with THBS1 
siRNA or control siRNA (5nM, Thermo Fisher Scientific) using lipofectamine 2000 for 24 
hours. Functional assays were performed in 48 hours. 
 
2.18 EMV-incorporated miR-92 were absorbed into recipient ECs 
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HCAEC (1*105) were transfected with 20 nM of cyanine 3 (Cy3)-labeled miR-92 (Riboxx) 
using HiPerFect (QIAGEN). The day after transfection, ECs were washed three times 
with PBS, and the medium was switched to serum-free medium. After incubation for 24 
hours, the serum-free culture medium was collected and used for EMV generation as 
previously described(Jansen, et al., 2013, Rautou, et al., 2011, Jansen, et al., 2012). 
Then EMV were labeled with PKH67 (Sigma-Aldrich) according to the manufacturer’s 
instructions. PKH67-labeled EMV were washed twice with PBS. To further evaluate the 
uptake of EMV into cultured ECs, ECs were incubated with PKH67-labeled EMV for 6 
hours. And then nuclei were stained with 4′,6-diamidino-2-phenylindole（DAPI，Vector 
labaratories）. Zeiss Axiovert 200M microscope and AxioVision software were used to 
visualize the uptake of EMV-incorporated miR-92 into recipient ECs. 
 
2.19 miR-92 expression calculation in target ECs using copy number 
HCAEC in basal medium were deprived of growth media supplements and coincubated 
with EMV, EMVmiR-92-downregulated, EMVmock-transfected or vehicle for 24 hours. The absolute 
expression of miR-92 was determined by obtaining standard curves with different 
concentration of miR-92 mimic (Applied Biosystems) as templates. Logarithmic values of 
oligonucleotide concentrations and Ct values were plotted. The copy number was 
calculated from the oligonucleotide concentration and the molecular mass of the 
transcript as described(Jansen, et al., 2013). 
 
2.20 Western Blot 
HCAEC in basal medium were deprived of growth media supplements and coincubated 
with EMV, EMVmiR-92-downregulated, EMVmock-transfected or vehicle for 48 hours. Then, HCAEC 
were homogenized with RIPA buffer (150 mM NaCl, 1.0% Nonidet P-40, 0.5% 
deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0) containing 1 mM Na3VO4, 5mM NaF 
and protease inhibitor cocktail (Roche) at 4°C. Protein concentration was measured 
using Lowry protein assay (BioRad). Equal amounts of proteins (30 μg) were loaded into 
12% SDS electrophoresis, transferred onto PVDF membranes and blocked with 5% dry 
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milk for 1 hour. Blots were incubated with the appropriate primary antibodies: 
anti-thrombospondin 1 (anti-THBS1, Abcam); anti-GAPDH (Hytest). Detection was 
performed using the appropriate secondary antibody (Anti-Rabbit IgG H,L (HRP), Abcam) 
and proteins were revealed by chemiluminescence using the ECL kit (GE healthcare). 
GAPDH was used as the loading control. 
  
2.21 Target mRNA expression analysis by real-time PCR 
HCAEC in basal medium were deprived of growth media supplements and co-incubated 
with EMV, EMVmiR-92-downregulated, EMVmock-transfected or vehicle for 24 hours. Total RNA was 
isolated out of HCAEC by TRIzol (Invitrogen) extraction method according to instruction 
of the manufacturer. RNA was quantified using Nanodrop spectrophotometer. Then, 1μg 
of the isolated total RNA was reversely transcribed using Omniscript reverse transcription 
kit (QIAGEN) according to the manufacturer's protocol. The expression of the following 3 
genes (Assay ID; Applied Biosystems) were quantified using a 7500 Fast 
Real-Time PCR System: THBS1 ((Hs00962908_m1); TEK (Hs00945146_m1); ANGPT1( 
Hs00919202_m1). The data was presented as the fold change in mRNA expression 
normalized to GAPDH (fold change = 2−ΔΔCT). 
 
2.22 Statistical analysis 
Normally distributed continuous variables were presented as mean ± SD. Continuous 
variables were tested for normal distribution with the use of the Kolmogorov–Smirnov 
test. Categorical variables are given as frequencies and percentages. For continuous 
variables, Student t test or Mann-Whitney U was used for comparison between 2 groups. 
For the comparison of >2 groups, the 1-way ANOVA with Bonferroni’s correction for 
multiple comparisons test was used. The Chi square test was used for categorical data 
that result from classifying objects. Binary logistic regression was applied to identify 
factors that were independently associated with miR-92. All tests were 2-sided, and 
statistical significance was assumed when the null hypothesis could be rejected at 
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p < 0.05. Statistical analysis was performed with IBM SPSS Statistics version 20 (USA) 
and GraphPad Prism 7. 
All authors attest to the accuracy and completeness of the data and all analyses and 
confirm that the study was conducted according to the protocol.
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3. Results 
3.1 Study design 
Between August 2012 and July 2013, 233 patients presenting with symptoms of stable 
CAD or ACS in our outpatient and emergency department were enrolled in the study. To 
identify alterations of MV-miR expression between stable CAD and ACS patients, we first 
performed miR screening. Specifically, miR profile in isolated circulating MV from stable 
CAD (n=5) and ACS patients (n=5) was assessed using taqman miR array. To validate 
miR array results, another 223 patients were screened for inclusion. Among those, 43 
patients with malignant (n=8), inflammatory diseases (n=15), severe hepatic or renal 
dysfunction (n=13) or declination of participation (n=7) were excluded from the study. 
Finally, a total of 180 patients were prospectively included (Figure 1). Patients were 
classified into 3 groups: Angiographic exclusion of obstructive coronary artery disease 
(<50% stenosis of a major coronary artery, named as no CAD (NCAD), n=41), stable 
CAD (n=77) and acute coronary syndrome (ACS, n=62, Figure 1, Table 1). 
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Fig. 1:Study flow  
According to the study protocol, we first performed miR screening. MiR profile in isolated circulating MV 
from stable CAD (n=5) and ACS patients (n=5) were assessed using taqman miR array. To validate miR 
array results, a total of 180 patients with angiographically excluded CAD (n=41), stable CAD (n=77) and 
ACS (n=62) were prospectively included in the study. Circulating MV were isolated from patients’ plasma 
using ultracentrifugation. MiRs derived from MV were analyzed by real-time PCR. CAD indicates coronary 
artery disease; ACS, acute coronary syndrome; MV, microvesicle; MiR, microRNA. 
 
Validation cohort (n=223) 
Excluded (n=43) 
-Chronic inflammatory disease (n=15) 
-Acute kidney or liver failure(n=13) 
-Malignant disease (n=8) 
-Declined to participate (n=7)
Inclusion of 180 patients in the study
No CAD (n=41) Stable CAD (n=77) ACS (n=62)
Isolation of circulating MVs from blood
MiRs analysis in MVs
Screening cohort  

Stable CAD (n=5) and ACS (n=5)
Taqman miR array
Isolation of circulating MVs from blood
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3.2 Baseline characteristics 
There was no difference regarding age among the three groups. Most of the patients 
(68.9%) enrolled were male, which was driven by higher numbers of male patients in the 
stable CAD and ACS group (P=0.001) 
Stable CAD and ACS patients were more likely to have diabetes (P=0.042), 
hyperlipoproteinemia (P=0.043), and a lower left ventricular ejection fraction (P=0.004) 
compared to NCAD patients. Stable CAD and ACS patients took more frequently ACE 
inhibitors, beta blockers, statins, aspirin and clopidogrel. Regarding the laboratory 
parameters, serum creatinine, glucose, HbA1c, glomerular filtration rate, triglycerides, 
LDL cholesterol and C-reactive protein leucocytes levels were similar in the three groups. 
Stable CAD and ACS patients showed reduced cholesterol (P=0.003) and HDL 
cholesterol (P=0.001) levels compared to NCAD patients (Table 1). 
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Tab. 1: Baseline characteristics of the study population  
 
*p values reflect the Pearson chi-square test results for categorical variables and analysis of variance for 
continuous variables. Continuous variables are presented as the mean ± SD, and categorical variables are 
presented as the percentage of patients. NCAD, non-coronary artery disease; Stable CAD, stable coronary 
artery disease; ACS, acute coronary syndrome; MI, myocardial infarction; PCI, percutaneous coronary 
intervention; ACE, angiotensin-converting enzyme; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; MV, microvesicle. Chronic kidney disease was defined as a glomerular filtration rate <60 
mL/min. 
Table1. Baseline characteristics of the study population
Characteristic
Total 
(n=180)
NCAD  
(n=41)
Stable CAD 
(n=77)
ACS 
(n=62)
P value
Age. year 65.3±11.3 63.4± 13.2 65.3±10.6 66.5±10.9 0.413
Gender. no. (%) 0.001
  Female 56(31.1%) 26(63.4%) 12(15.6%) 18(29.0%)
  male 124(68.9%) 15(36.6%) 65(84.4%) 44(71.0%)
Cardiovascular risk factors. (%)
  Arterial hypertension 141(78.3%) 30(73.2%) 60(77.9%) 51(82.3%) 0.545
  Hyperlipoproteinemia 94(52.2%) 16(39.0%) 39(50.6%) 39(62.9%) 0.043
  Family history 43(24.2%) 11(26.8%) 18(23.4%) 14(22.6%) 0.876
  Diabetes 55(30.6%) 7(12.2%) 23(29.1%) 25(40.3%) 0.042
  Smoking 43(23.9%) 7(17.1%) 24(31.2%) 14(22.6%) 0.209
  Body mass index. kg/m2 27.9±11.3 26.6±6.0 28.2±3.9 28.3±5.6 0.183
Medical history. (%)
  Previous bypass 21(11.7%) 0(0%) 9(11.7%) 12(19.4%) 0.011
  Previous MI (6 months) 45(25.0%) 0(0%) 33(42.9%) 12(19.4%) 0.001
  Previous stroke 7(3.9%) 2(4.9%) 1(1.3%) 4(6.5%) 0.275
  Chronic kidney disease 6(3.3%) 2 (4.9%) 1(1.3%) 3(4.8%) 0.421
PCI
  Previous 101(56.1%) 0 (0%) 61(79.2%) 40 (64.5%) 0.001
  Current 90(50.0%) 0(0%) 48(62.3%) 42(67.7%) 0.001
Coronary artery disease. no. (%) 0.001
  1   Vessels 28(15.6%) 0(0%) 16(20.8%) 12(19.4%)
  2   Vessels 48(26.7%) 0(0%) 29(37.7%) 19(30.6%)
  3   Vessels 63(35.0%) 0(0%) 32(41.6%) 31(50.0%)
  Left ventricular ejection fraction. % 57.4±12.3 62.8±8.9 55.8±10.8 55.2±15.0 0.004
Medication on admission. no. (%)
  ACE inhibitors 114(63.3%) 14(34.1%) 58(75.3%) 42(67.7%) 0.001
  Angiotensin receptor blockers 34(18.9%) 10(24.4%) 11(14.3%) 13(21.0%) 0.359
  Beta blockers 150(83.3%) 25(61.0%) 69(89.6%) 56(90.3%) 0.001
  Calcium channel blockers 33(18.3%) 7(17.1%) 11(14.3%) 15(24.2%) 0.315
  Diuretics 77(42.8%) 21(51.2%) 27(35.1%) 29(46.8%) 0.176
  Statins 148(82.2%) 15(36.5%) 75(97.4%) 58(93.5%) 0.001
  Nitrates 9(5.0%) 1(2.4%) 5(6.5%) 3(4.8%) 0.628
  Aspirin 140(77.8%) 8(19.5%) 75(97.4%) 57(91.9%) 0.001
  Clopidogrel 54(30.0%) 1(2.4%) 23(29.9%) 30 (48.4%) 0.001
Laboratory parameters
  Glucose 117.3±46.5 108.8±35.9 120.4±48.5 119.5±50.5 0.412
  Hb A1c(%) 6.2±0.9 6.0±0.5 6.3±0.9 6.3±1.0 0.108
  Serum creatinine. mg/dL 1.0±0.3 0.9±0.4 1.0±0.3 1.0±0.3 0.166
  Glomerular filtration rate. mL/min 66.1±10.2 67.6±9.2 65.6±10.7 65.7±10.1 0.567
  Triglycerides. mg/dL 157.2±179.7 116.9±47.3 150.1±82.9 192.7±286.9 0.100
  Cholesterol. mg/dL 184.4±47.7 206.4±40.4 178.6±44.2 177.1±52.4 0.003
  HDL cholesterol. mg/dL 49.3±17.5 63.9±22.1 45.3±12.3 44.6±14.2 0.001
  LDL cholesterol. mg/dL 112.6±37.7 121.6±32.2 109.7±33.1 110.3±45.4 0.221
  C-reactive protein. mg/L 5.2±11.2 3.3±4.6 5.7±13.9 5.7±10.4 0.483
  Leucocytes. 109/L 7.3±2.1 6.9±2.3 7.4±2.1 7.3±2.1 0.413
CD marker
  Concentration of AnnV+ MV/µl 738.0±1866.7 557.8 ±887.6 716.7±1300.7 883.6±2748.9 0.683
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3.3 miR selection and detection in circulating MV 
Circulating miRs protected by circulating MV regulate the progression of coronary artery 
disease(Boulanger, et al., 2017) and are associated with cardiovascular 
outcomes(Jansen, et al., 2014). However, the expression profile of MV-miRs in patients 
with or without CAD has not been systemically explored so far. Therefore, miR profile in 
isolated circulating MV from stable CAD (n=5) and ACS patients (n=5) were assessed 
using taqman miR array. Among the multiple differentially expressed miRs between 
stable CAD and ACS patients (Figure 2), 9 miRs with known regulatory roles in the 
development and progression of atherosclerosis and coronary artery disease were 
selected for prospective quantification in our validation cohort of 180 patients without 
CAD, stable CAD or ACS: miR-21(Thum, et al., 2008), miR-26(Jansen, et al., 2016), 
miR-92(Hinkel, et al., 2013), miR-126(Jansen, et al., 2013), miR-139(Voellenkle, et al., 
2010), miR-199(Rane, et al., 2009) and miR-222(Jansen, et al., 2015), miR-let7(Yu, et al., 
2011), miR-30(Chen, et al., 2014, Shen, et al., 2015). 
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Fig. 2: MV-miRs screening 
Volcano plot analysis showed miR profile in isolated circulating MV from stable CAD and ACS patients as 
determined TaqMan miR array (n=5). The horizontal line displays the border for significant regulation. 
Points above that line represent significantly regulated miRs (P<0.05(−log10)). MV, microvesicle. 
 
Analysis of miR expression pattern in isolated MV from NCAD, stable CAD and ACS 
patients showed no difference regarding miR-21, miR-26, miR-126, miR-139, miR-199, 
miR-222, miR-let7 and miR-30. In contrast, miR-92 was significantly increased in stable 
CAD and ACS patients compared to NCAD patients (*P<0.05, Figure 3). Based on these 
observations, we sought to further characterize the role of MV-incorporated miR-92. 
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Fig. 3: miR expression analysis in patients with or without CAD 
miR expression was analyzed in circulating MV in patients with angiographically excluded CAD (No CAD, 
n=41), stable CAD (n=77) and ACS (n=62) patients. Values were normalized to cel-miR-39 and were 
expressed as 2-[CT(miR)-CT(cel-miR-39)] log10. Data are presented as mean±SD (*P<0.05, by 1-way ANOVA with 
Bonferroni’s multiple comparisons test). MiR indicates microRNA; MV, microvesicle; CAD, coronary artery 
disease; ACS, acute coronary syndrome. 
 
Comorbidities such as hypertension and diabetes or medication potentially affect 
circulating MV-bound miRs levels. However, binary logistic regression demonstrated that 
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higher or lower levels of miR-92 were not associated with any comorbidities (Table 2). 
Furthermore, miR-92 levels were independent of any drug therapy (Table 2).  
 
Tab. 2: Association of the level of miR-92 with baseline characteristics  
 
The coefficient of the continuous variables was relative to 1-U differences. Binary logistic regression 
according to the median of miR-92 level. ACE indicates angiotensinconverting enzyme; CAD, coronary 
artery disease; Exp(B), exponentiation of the B coefficient; miR, microRNA. 
Exp(B) (95% CI) P Value
Age 1.020(0.982 to 1.060) 0.304
Male sex 1.627 (0.651 to 4.069) 0.298
Body mass index 0.924 (0.845 to 1.010) 0.080
Arterial hypertension 0.762 (0.296 to 1.963) 0.574
Hyperlipoproteinemia 0.824 (0.374 to 1.813) 0.630
Diabetes 1.859 (0.991 to 3.488) 0.053
Family history of CAD 0.780 (0.309 to 1.966) 0.598
Smoking 1.537 (0.616 to 3.832) 0.357
History of myocardial infarction 0.748 (0.279 to 2.002) 0.563
Chronic kidney disease 0.430 (0.279 to 5.498) 0.516
Number of diseased vessels 0.785(0.608 to 1.014) 0.064
Left ventricular ejection fraction 0.995 (0.963 to 2.002) 0.754
Previous PCI 0.560 (0.210 to 1.028) 0.247
Current  PCI 0.815 (0.327 to 2.030) 0.661
Angiotensin Converting Enzyme inhibitors (ACEI)    0.915 (0.275 to 3.047) 0.885
Angiotensin receptor blockers (ARB) 0.658 (0.171 to 2.530) 0.542
Beta blockers 1.907 (0.600 to 6.063) 0.274
Calcium channel blockers (CCB) 0.828 (0.282 to 2.430) 0.732
Diuretics 1.002 (0.417 to 2.409) 0.997
Statins 1.229 (0.329 to 4.595) 0.759
Nitrates 8.061 (0.719 to 90.369) 0.091
Aspirin 1.160 (0.295 to 4.566) 0.832
Table 2. Association of the level of miR-92 with baseline characteristics
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3.4 miR-92 expression in MV, exosomes and vesicle-free plasma 
Circulating miRs in plasma can be transported within extracellular vesicles (exosomes, 
MV, apoptotic bodies) or bound to proteins (high-density lipoprotein, Ago-2). Both routes 
provide remarkable stability and resistance to degradation from endogenous RNase 
activity. Next, we aimed to explore the plasma compartments (exosomes, MV, vesicle- 
free plasma) in which miR-92 is mainly expressed. Consequently, MV, exosomes, and 
vesicle-free plasma were collected by series of centrifugation steps, and miR-92 was 
analyzed in the sub-compartments of 10 patients with stable CAD. Electron microscopy 
confirmed a proper isolation of exosomes and MV according to the used protocol (Figure 
4A). miR-92 was detectable mainly in MV or vesicle-free plasma (Figure 4B).  
Because circulating MV compose different subspecies of membrane particles released 
from endothelium and blood cells, we sorted endothelial-, platelet-, and other cell-derived 
MV using flow cytometer to explore the cellular origins of MV-bound miR-92 as previously 
described(Jansen, et al., 2016, Jansen, et al., 2014). Overall, miR-92 showed the highest 
expression in CD31+/CD42b− endothelial cell-derived MV (EMV), compared to 
CD31+/CD42b+ platelet-derived MV (PMV) and CD31−/CD42b− MV (Figure 4C). Similarly, 
in vitro, miR-92 also showed the highest expression in EMV, compared to PMV and 
monocyte-derived MV (MMV, Figure 4D). These results suggest that miR-92 is 
selectively packaged into EMV in patients and in vitro.
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Fig. 4: miR-92 expression in plasma subpopulations  
(A) Expression of miR-92 in plasma compartments. MV and exosomes were isolated using 20,000g and 
100,000g centrifugation. Characterization of MV, exosomes and the last supernatant were performed using 
electron microscopy. Magnification ×46,000. (B) MiR-92 was quantified in MV, exosomes, and 
vesicles-free supernatant by real-time PCR (*P<0.05, n=6, by 1-way ANOVA with Bonferroni’s correction 
for multiple comparisons test). Cel-miR-39 was used as control. (C) Endothelial cell–derived 
(CD31+/CD42b-), platelet-derived (CD31+/CD42b+), and other cell–derived MV (CD31-/CD42b-) were 
collected from 10 plasma samples of CAD patients, and miR-92 expression was analyzed in MV 
subspecies in vivo by real-time PCR (*P<0.05, n=10, by 1-way ANOVA with Bonferroni’s correction for 
multiple comparisons test). Cel-miR-39 was used as control. (D) EMV, PMV and MMV were isolated from 
corresponding cells and miR-92 expression was analyzed in MV subspecies in vitro by real-time PCR 
(*P<0.05, **P<0.01, n=3-5, by 1-way ANOVA with Bonferroni’s correction for multiple comparisons test). 
RNU6B was used as an endogenous control. MV indicates microvesicle; CAD, coronary artery disease; Ex, 
exosomes; Sup, supernatant. EMV, endothelial cell–derived microvesicle; PMV, platelet-derived 
microvesicle; MMV, monocyte-derived microvesicle. 
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3.5 oxLDL stimulation in vitro increases EMV-incorporated miR-92 expression in a 
STAT3-dependent mechanism 
As MV-incorporated miR-92 was significantly increased in CAD patients and endothelial 
cell-derived MV were shown to be the major source of miR-92-containing MV, we next 
explored the effect of atherosclerotic conditions in vitro on miRs expression in ECs and 
EMV. As an independent risk factor of atherosclerosis, several lines of evidence indicate 
that low-density lipoprotein (LDL) and especially it’s oxidized form (oxLDL) play a key role 
in endothelial dysfunction and atherogenesis(Chen, et al., 2002, Pirillo, et al., 2013). To 
explore whether oxLDL might affect miRs levels in ECs and EMV, ECs were incubated 
with oxLDL for 24 hours and EMV were isolated subsequently. Real-time PCR analysis of 
the nine selected miRs revealed that mainly miR-92, but also miR-222, miR-26 and 
miR-let7 were selectively sorted into EMV after oxLDL stimulation (Figure 5A)  
To further investigate the link between oxLDL and miR-92, we quantified miR-92 
expression in ECs and EMV after stimulation with different oxLDL concentrations. OxLDL 
stimulation significantly increased miR-92 expression both in EMV and ECs in a 
dose-dependent effect (Figure 5B and 5C). In summary, our findings indicate that oxLDL 
induces cellular miR-92 expression and promotes the packaging of miR-92 from ECs into 
EMV. 
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that 
controls a battery of genes involved in the regulation of a variety of biological processes. 
Previous studies identified a highly conserved STAT3-binding site in the promoter of the 
EFCAB12 gene, which encodes the entire miR-17-92 cluster(Brock, et al., 2011). To 
examine the direct effect of STAT3 activation on miR-92 expression in ECs and EMV, we 
selectively blocked STAT3 activity using a STAT3 inhibitor in ECs and EC-derived MV. 
miR-92 expression analysis revealed that STAT3 inhibition significantly reduced miR-92 
expression in ECs and EMV in a dose-dependent mechanism (Figure 5D and 5E), 
highlighting a regulatory role of STAT3 in endothelial miR-92 expression and MV 
packaging. 
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Fig. 5: OxLDL increases miR-92 expression in ECs and EMV  
(A) miR-let7, miR-21, miR-26, miR-30, miR-126, miR-222, miR-92, miR-21 and miR-199 ere analyzed in 
oxLDL EMVs by real-time PCR (*P<0.05, **P<0.01, ***P<0.001, n=5, by 1-way ANOVA with Bonferroni’s 
correction for multiple comparisons test). Non-treated EMV served as control. (B, C) MiR-92 was analyzed 
in ECs and EMVs after stimulation with different oxLDL concentrations by real-time PCR (*P<0.05, 
**P<0.01, n=5, by 1-way ANOVA with Bonferroni’s correction for multiple comparisons test). (D, E) MiR-92 
was measured in ECs and EMVs after stimulation with different concentrations of STAT3 inhibitor by 
real-time PCR (***P<0.001, **P<0.01, n=5-6, by 1-way ANOVA with Bonferroni’s correction for multiple 
comparisons test). RNU6B was used as an endogenous control in real-time PCR. OxLDL indicates 
oxidized low-density lipoprotein; EMVs indicates endothelial cell-derived microvesicles; ECs, endothelial 
cells; STAT3, signal transducer and activator of transcription 3. 
 
3.6 miR-92 in EMV regulates target ECs function 
Increasing evidence suggests that MV emerge as major transport vehicles for miRs and 
that the effects of MV depend on the MV-containing miRs expression. To study the 
biological function of incorporated miR-92 in EMV, we investigated first whether MV 
miR-92 can be internalized by recipient cells. To visualize the transport of MV miR-92 
derived from ECs into recipient cells, we transfected donor ECs with Cy3 labeling miR-92 
(Cy3-miR-92) and isolated Cy3-miR-92 containing EMV were isolated from donor ECs. 
Then the EMV were labeled with PKH67. After incubation with labeled EMV, 
co-localization of Cy3-miR-92 (red) and PKH67 (green) was observed in most recipient 
cells by using fluorescent microscopy (Figure 6A). Furthermore, copy number assays 
using real-time PCR confirmed an efficient transfer of miR-92 into recipient cells via EMV 
(Figure 6B)
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Fig. 6: EMV-incorporated miR-92 is transferred into recipient ECs 
(A) Cy3-labeled miR-92 was transfected into ECs and EMV were derived, then EMV labeled with PKH67. 
PKH67-labelled EMV that contained Cy3-labeled miR-92 were cultured with recipient ECs for 6 hours. 
Cells nuclei were stained with DAPI and pictures were taken. Bars: 10 μm. a) Nuclei were stained with 
DAPI (blue). b) EMV were labeled with PKH67 (green) c) Red showed Cy3-labeled miR-92. d) The 
Cy3-miR-92 signals co-localized with PKH67. e) As a negative control for detection of the Cy3 signals, ECs 
were cultured with non-labeled miR-92 within EMV. f) As a negative control for PKH67, ECs were cultured 
with unlabeled EMV. (B) MiR-92 expression in target ECs that were treated with EMV or vehicle was 
quantified using copy number analysis (***P<0.001, n=4, by student t test). EMV indicates endothelial 
cell-derived microvesicle; Cy3, cyanine 3; EC, endothelial cell; DAPI, 4′,6-diamidino-2-phenylindole. 
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Next, we aimed to explore the biological function of EMV-incorporated miR-92. As 
miR-92 has been shown to be a major regulator of angiogenesis(Zhang, et al., 2014), we 
investigated whether miR-92 in EMV can functionally regulate target EC migration, 
proliferation and tube formation. Therefore, miR-92 inhibitor was used to inhibit miR-92 
expression in EC and EC-derived EMV to generate EMVmiR-92-downregulated and the 
corresponding control group (EMVmock-transfected). Efficient miR-92 downregulation in EMV 
parent cells and EMV by using inhibitor was confirmed by real-time PCR (Figure 7). Copy 
number experiments revealed that downregulation of miR-92 in EMV resulted in a 
reduced transfer of miR-92 in recipient cells (Figure 8). Treatment of target ECs with 
EMV promoted EC migration, proliferation and tube formation in vitro (Figure 9). 
Importantly, EMV-mediated effects on recipient ECs were abolished using 
EMVmiR-92-downregulated, indicating that miR-92 in EMV functionally regulates target ECs 
function and phenotype by promoting angiogenic processes (Figure 9). 
 
 
Fig. 7: miR-92 expression in EMV and EMV donor cells  
ECs were transfected with miR-92 inhibitor or the corresponding mock and then subjected to basal media 
to generate EMV. MiR-92 expression was analyzed in EMV and EMV donor cells by real-time PCR 
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(*P<0.05, **P<0.01, n=5, by 1-way ANOVA with Bonferroni’s multiple comparisons test). RNU6B was used 
as an endogenous control. EMV indicates endothelial cell-derived microvesicle; ECs, endothelial cells. 
 
Fig. 8: EMV-incorporated miR-92 is transferred into target ECs 
miR-92 expression in recipient ECs that were treated with EMV, EMVmiR-92-downregulated, EMVmock-transfected by 
copy number analysis (*P<0.05, ***P <0.001, n=4, by 1-way ANOVA with Bonferroni’s multiple 
comparisons test). EC indicates endothelial cell; EMV, endothelial cell-derived microvesicle.  
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Fig. 9: miR-92 regulates EC migration, proliferation and angiogenesis via EMV 
EMVmiR-92-downregulated and EMVmock-transfected was separately derived from miR-92 inhibitor–transfected and 
mock-transfected parent cells. ECs in basal media were co-incubated with EMV, EMVmiR-92-downregulated, 
EMVmock-transfected or vehicle. (A) Scratch migration assay was performed and representative images of cells 
migrating into the scratched region were shown. Quantitative analysis of migration was measured as a 
percentage of total cell-free area (*P<0.05, **P <0.01, ***P<0.001, n=6, by 1-way ANOVA with Bonferroni’s 
multiple comparisons test). (B) Boyden chamber migration assay was performed using ECs. Data 
represent the numbers of migrated cells (**P<0.01, ***P<0.001, n=5, by 1-way ANOVA with Bonferroni’s 
multiple comparisons test). (C) BrdU incorporation was determined by immunofluorescence (red). Nuclei 
were stained with DAPI (blue). The percentage of BrdU-positive cells was compared (*P<0.05, **P<0.01, 
Control EMV
EMV 
miR-92-downregulated  
EMV 
mock transfected  
E 
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***P<0.001, n=5, by 1-way ANOVA with Bonferroni’s multiple comparisons test). Magnification ×100. (D) 
The incorporation of BrdU was normally analyzed in flow cytometry by labelling with a conjugate anti-BrdU 
antibody (*P<0.05, n=3, by 1-way ANOVA with Bonferroni’s multiple comparisons test). (E) Tube formation 
assays of ECs. Capillary tubes were photographed with microscope. Tube junctions and nodes were 
measured and quantitatively analyzed using Image-Pro Plus software ((*P<0.05, **P<0.01, n=3, by 1-way 
ANOVA with Bonferroni’s multiple comparisons test). EMV indicates endothelial cell-derived microvesicle; 
EC, endothelial cell; BrdU, bromodeoxyuridine and DAPI, 4′,6-diamidino-2-phenylindole. 
 
3.7 EMV-mediated transfer of functional miR-92 regulates angiogenesis in recipient ECs 
in a THBS1-dependent mechanism 
Finally, we aimed to investigate the underlying mechanism of EMV-transferred miR-92 in 
the regulation of angiogenic functions in recipient ECs. RT² Profiler PCR array analysis 
was performed to measure the expression of 84 key genes involved in modulating the 
biological processes of angiogenesis. As miRs regulate cellular phenotype by 
downregulating target mRNAs, we focused on downregulated genes in recipient ECs 
after treatment with vehicle, EMV and EMVmiR-92-downregulated. Profiler PCR array results 
showed that 53 genes were downregulated by EMV compared to control treatment, and 
40 genes were downregulated by EMV compared to EMVmiR-92-downregulated treatment. The 
five most downregulated genes in EMV vs. control and EMV vs. EMVmiR-92-downregulated 
were separately selected and further explored (Figure 10A-C). Among those, 3 genes 
were simultaneously downregulated in response to EMV treatment compared to control 
and EMVmiR-92-downregulated: Thrombospondin 1(THBS1), TEK Receptor Tyrosine Kinase 
(TEK) and Angiopoietin 1 (ANGPT1, Figure 10C). Single real-time PCR experiments 
showed that only THBS1, a known target of miR-92(Italiano, et al., 2012), was 
downregulated in target ECs by EMV in a miR-92-dependent manner (Figure 10D-E). 
Furthermore, western blot experiments confirmed a miR-92–dependent downregulation 
of THBS1 expression in target ECs after EMV treatment (Figure 10F). These findings are 
consistent with the initial array results showing no change of THBS1 expression in target 
ECs after treatment with EMVmiR-92-downregulated compared to control. Given the known 
evidence of THBS1 as a negative regulator of EC migration and proliferation(García-
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Conesa, et al., 2009), further experiments were performed to evaluate whether miR-92 in 
EMV can inhibit THBS1 expression in target ECs and thereby promote EC migration and 
proliferation. Therefore, ECs were transfected with small interfering RNA against THBS1 
or scrambled small interfering RNA (control small interfering RNA). Efficient THBS1 
downregulation in target cells by using interfering RNA was confirmed by real-time PCR 
(Figure 11). Downregulation of THBS1 significantly increased EC migration and 
proliferation, confirming that THBS1 as a negative regulator of ECs migration and 
proliferation (Figure 12). 
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Fig. 10: EMV-incorporated miR-92 regulates angiogenesis in recipient ECs in a THBS1-dependent 
mechanism 
ECs in basal media were co-incubated with EMV, EMVmiR-92-downregulated or vehicle for 24 hours. (A) Scatter 
Plot showing differentially regulated genes after EMV and control treatment. The five strongest 
downregulated genes after EMV treatment are highlighted (n=3). (B) Scatter Plot showing differentially 
regulated genes between after EMV and EMVmiR-92-downregulated treatment by PCR array. The five strongest 
downregulated genes after EMV treatment are highlighted (n=3). (C) Summary of the top 5 downregulated 
genes after EMV treatment compared to control and EMVmiR-92-downregulated. RPLP0 was used as endogenous 
control in PCR array. The grey background highlights the three genes which were downregulated by EMV 
in both analysis (compared to control and compared to EMVmiR-92-downregulated). (D) TEK expression of ECs 
that were treated with EMV, EMVmiR-92-downregulated, EMVmock-transfected or vehicle was determined by real-time 
PCR. (E) ANGPT1 expression of ECs that were treated with EMV, EMVmiR-92-downregulated, EMVmock-transfected or 
vehicle was determined by real-time PCR (n=3, by 1-way ANOVA with Bonferroni’s multiple comparisons 
test). GAPDH was used as an endogenous control in real-time PCR. (F) THBS1 expression in target ECs 
that were treated with EMV, EMVmiR-92-downregulated, EMVmock-transfected or vehicle was determined by real-time 
PCR (*P<0.05, n=3, by 1-way ANOVA with Bonferroni’s multiple comparisons test). GAPDH was used as 
an endogenous control. (G) THBS1 expression in target ECs that were treated with vehicle, EMV, 
EMVmiR-92-downregulated or EMVmock-transfected was analyzed by western blot. EMV indicates endothelial 
cell-derived microvesicle; EC, endothelial cell; miR, microRNA; THBS1, thrombospondin 1; RPLP0, 
THBS1
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ribosomal protein lateral stalk subunit P0. TEK, TEK Receptor Tyrosine Kinase and ANGPT1, angiopoietin 
1. 
 
 
Fig. 11: THBS1 expression in ECs 
ECs were transfected with THBS1 siRNA or scrambled control siRNA. Non-transfected ECs served as 
control. THBS1 expression was analyzed in ECs (*P<0.05, n=4, by 1-way ANOVA with Bonferroni’s 
multiple comparisons test). GAPDH was used as an endogenous control. (*P<0.05, n=4, by 1-way ANOVA 
with Bonferroni’s multiple comparisons test). EC indicates endothelial cell; THBS1, thrombospondin 1. 
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Fig. 12: THBS1 negatively regulates migration and proliferation in ECs 
ECs were transfected with THBS1 siRNA or scrambled control siRNA. Non-transfected ECs served as 
control. (A) Scratch migration assay was performed and representative images of cells migrating into the 
scratched region were shown. Quantitative analysis of migration was measured as a percentage of total 
Control THBS1 siRNA-transfected Control siRNA-transfected
B 
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cell-free area (*P<0.05, **P<0.01, n=6, by 1-way ANOVA with Bonferroni’s multiple comparisons test). (B) 
BrdU incorporation was determined by immunofluorescence (red). Nuclei were stained with DAPI (blue). 
The percentage of BrdU-positive cells was compared (***P<0.001, n=10, by 1-way ANOVA with 
Bonferroni’s multiple comparisons test). Magnification ×100. THBS1 indicates thrombospondin 1; EC, 
endothelial cell; BrdU, bromodeoxyuridine and DAPI, 4′,6-diamidino-2-phenylindole. 
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4. Discussion 
miRs are currently explored as biomarkers in a wide range of cardiovascular conditions 
including atherosclerotic diseases. Circulating miRs are detectable and remarkably 
stable in body fluids such as blood and urine. Circulating MV represent major transport 
vehicles for miRs by separating them from circulating RNase(Boon and Vickers, 2013). 
Increasing evidence suggests that CAD patients show elevated levels of circulating MV, 
which might be actively involved in the progression of vascular dysfunction in 
atherosclerotic conditions(Jansen, et al., 2014). However, so far, the biological content of 
circulating MV in patients with or without CAD is vastly unknown. 
MV-bound miRs, compared to freely circulating miRs, were shown to predict 
cardiovascular events in patients with stable CAD(Jansen, et al., 2014). Therefore, we 
focused on analyzing the expression of MV-incorporated miRs in this study. Analysis of 
circulating MV-miRs showed significantly increased levels of miR-92 in patients with 
stable CAD and ACS in comparison to patients without CAD. These findings emphasize 
a potential role for miR-transporting MV in the regulation of vascular health, which is 
altered under atherosclerotic conditions. Next, we further explored cellular origins of 
MV-bound miR-92 in CAD patients. It has been shown that miR-92 is highly expressed in 
various cell types, such as ECs, platelets and monocyte-lineage cells(Zhang, et al., 2014, 
Zhang, et al., 2015, Sisk, et al., 2012). The high expression of miR-92 in sorted 
patient-derived CD31+/CD42b- MV on one hand and in EC-derived EMV in vitro 
suggests that circulating MV-miR-92 is mainly of endothelial cell origin, which is in line 
with an increasing body of evidence(Zhang, et al., 2017, Chen, et al., 2014). 
In analogy to our clinical findings, in vitro experiments demonstrated that miR-92 was 
dose-dependently up-regulated after oxLDL stimulation as pro-atherogenic stimulus in 
ECs and EC-derived EMV. Taken together, these findings emphasize that miR-92 is 
predominately upregulated in ECs and EMV in atherosclerotic conditions. 
Previous studies have shown that miR-92 expression is controlled by a large variety of 
transcription factors(Concepcion, et al., 2012). In this context, miR-92 expression was 
upregulated by STAT3 in ECs and lung cancer cells(Loyer, et al., 2013, Lin, et al., 2013). 
However, whether STAT3 could be involved in the specific regulation of miR-92 in MV is 
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unknown. Our studies unveil a critical role for STAT3 in regulating miR-92 expression in 
MV in a dose-dependent way.  
Evidence suggested that loss-of-function of miR-92 resulted in smaller embryos and 
immediate postnatal death of all animals. This was likely due to severely ventricular 
septal defects in the hearts of mice lacking miR-92(Mendell, 2008). Furthermore, miR-92 
has been shown to be a crucial regulator of angiogenesis and vascular integrity. Daniel et 
al. showed that inhibition of miR-92 enhances re-endothelialization and prevents 
neointimal lesion formation after endovascular injury(Daniel, et al., 2014). In line with 
these findings, inhibition of miR-92 increased endothelial proliferation and migration in 
vitro and reduced neointimal formation after balloon injury or arterial stenting in 
vivo(Iaconetti, et al., 2012). Consistently, Hinkel et al. showed that an efficient inhibition 
of miR-92 exhibits pleiotropic beneficial effects, which may contribute to the improved 
recovery of heart function after ischemia/reperfusion injury in a preclinical pig 
model(Hinkel, et al., 2013). Taken together, these results demonstrate that miR-92 plays 
an important role in developmental and pathological angiogenesis. Whereas inhibition of 
miR-92 seems to mediate vascular regeneration and reduce vascular remodeling, the 
functional role of miR-92 in EMV is unclear. To explore whether EMV-incorporated 
miR-92 might play a functional role in the regulation of vascular performance, we first 
explored whether EMV-bound miR-92 was taken up by target ECs. By using Cy3-labeled 
miR-92 and PKH67-labeled EMV, we found that miR-92 was transferred via EMV into 
recipient ECs. Next, loss-of-function experiments showed that EMV promoted EC 
migration, proliferation and tube formation in a miR-92-dependent manner in vitro, which 
was abrogated by downregulation of miR-92 in EMV. Consistent with our results, Umezu 
et al have shown that exogenous miR-92 application via exosomes enhanced EC 
migration and tube formation(Umezu, et al., 2013). Conversely, Bonauer et al 
demonstrated that overexpression of miR-92 in ECs repressed angiogenesis both in vitro 
and vivo(Bonauer, et al., 2009). Based on our findings and the above evidence, 
intracellular levels of miR-92 in ECs can be in elevated in two ways: 1) direct upregulation 
using transfection of precursor miR-92; 2) delivery of exogenous miR-92 via biological 
transporting cargoes, e.g. exosomes or MV. Apparently, though the two ways both result 
in augmented cellular levels of miR-92, the subsequent cellular function and phenotype 
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can differ. In summary, the role of miR-92 in the regulation of angiogenesis is still 
controversial and may vary depending on the experimental model and methods of 
regulating miR-92.  
miR-92 regulates angiogenesis and has multiple mRNA targets. Bonauer et al 
demonstrated that miR-92 could directly target integrin α5 (ITGA5) (Bonauer, et al., 
2009). Likewise, Zhang et al demonstrated that phosphatase and tensin homolog (PTEN) 
is a direct target of miR-92, the PTEN plays a central role in regulating 
angiogenesis(Zhang, et al., 2014). Our PCR-based gene expression array results 
suggested that THBS1, TEK, ANGPT1 were downregulated by EMV-bound miR-92 in 
target ECs. However, single real-time PCR experiments revealed that only THBS1 was 
inhibited by EMV-miR-92. THBS1 has been one the first endogenous inhibitors of 
angiogenesis which has been identified(Tandle, et al., 2004). THBS1 inhibits 
angiogenesis directly by interacting with specific receptors and stimulating Fas/Fas 
ligand-mediated apoptosis of ECs, or indirectly by modulating the activity of several 
angiogenic factors(Italiano, et al., 2012). Interestingly, tumor angiogenesis is also 
associated with a significantly upregulated cellular expressions of miR-92, leading to 
downregulated THBS1, and the therapeutic efficacy of a THBS1 inhibitor has been 
evaluated in a phase 2 trial(Italiano, et al., 2012, Gordon, et al., 2008, Dews, et al., 2006). 
Finally, our functional in vitro experiments confirmed that THBS1 negatively regulates EC 
migration and proliferation, cellular processes mediating angiogenesis. 
In summary, we show that clinical and experimental atherosclerotic conditions promote 
the packaging of miR-92 into EMV. EMV contain and transfer functional miR-92 into 
recipient ECs, inhibit THBS1 expression, and promote EC migration, proliferation and 
tube formation in a miR-92-dependent manner (Figure 13). These results indicate that 
EMV can act as biological vectors delivering functional miR-92 into recipient ECs. Based 
on our findings, one can speculate that pro-atherogenic stimuli promote the release of 
miR-92-containing EMV as a messenger carrying a potentially regenerative signal that 
can be taken up by EC further downstream in the blood to promote angiogenesis in 
conditions of vascular damage. These results add new aspects to the role and function of 
miR-92 in EMV as a potential regenerative messenger in intercellular communication. 
However, some important questions remain and will be addressed in future studies. First, 
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the analysis of circulating miRs bound to other cargos than MV (e.g. HDL or Ago proteins) 
would be of interest for future studies. Second, only a selected number of miRs, based on 
own array results and previously published data, were analyzed. Finally, although we see 
a specific effect of miR-92 in EMV, we cannot rule out the influence of other miRs or 
bioactive molecules present in EMV in our findings. 
 
Fig. 13: Proposed mechanism 
In atherosclerotic conditions, miR-92 expression both in ECs and EMV is upregulated in a 
STAT3-dependent way. EMV released from parent ECs contain and transfer miR-92 into adjacent ECs. 
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MiR-92-mediated inhibition of THBS1 promotes adjacent ECs migration, proliferation and angiogenesis. 
ECs indicates endothelial cells; EMV indicates endothelial cell-derived microvesicle; THBS1 indicates 
thrombospondin 1. 
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5. Conclusion 
In this study, we provide evidence that clinical and experimental atherosclerotic 
conditions promote the packaging of functional miR-92 into MV. EMV-mediated transfer 
of functional miR-92 regulates angiogenesis in recipient ECs in a THBS1-dependent 
mechanism. 
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6. Summary 
Whether MV-miR expression is regulated in coronary artery disease (CAD) or not is 
unknown. We aimed to explore the expression of circulating MV-miRs in patients with 
CAD.   
A Taqman miR array revealed that certain MV-miRs are significantly regulated in patients 
with stable CAD compared to ACS patients. 180 patients with angiographically excluded 
CAD (n=41), stable CAD (n=77), and acute coronary syndrome (ACS, n=62) were 
prospectively studied. Nine miRs involved in the regulation of vascular performance were 
quantified in circulating MVs. Among these, miR-92 was significantly increased in 
patients with CAD compared to non-CAD patients. In vitro, oxLDL stimulation increased 
miR-92 expression in parent ECs and endothelial microvesicle (EMV). Labeling of 
miR-92 and EMVs demonstrated miR-92 was transported into recipient ECs. Knockdown 
of miR-92 in EMVs abrogated EMV-mediated effects on EC migration and proliferation 
and blocked vascular network formation in a matrigel plug. PCR-based gene profiling 
showed that the expression of THBS1 protein, a target of miR-92 and an inhibitor of 
angiogenesis, was significantly reduced in ECs by EMV. Knockdown of miR-92 in EMV 
abrogated EMV-mediated inhibition of the THBS1 gene and protein expression. 
In summary, we provide evidence that microvesicles-incorporated miR-92 is upregulated 
in patients with coronary artery disease. In vitro, oxidized LDL promotes the packaging of 
functional microRNA-92 from endothelial cells into microvesicles promoting angiogenic 
responses in recipient cells in a THBS1-dependent manner.  
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